Sprint Bioscience AB (publ) (FRA:5JA1)

Market Cap	28.28M +533.5%
Revenue (ttm)	15.45M +152.7%
Net Income	8.48M
EPS	0.09
Shares Out	n/a
PE Ratio	3.34
Forward PE	15.72
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	336
Open	0.2470
Previous Close	0.2700
Day's Range	0.2470 - 0.2470
52-Week Range	0.0174 - 0.3520
Beta	n/a
RSI	54.95
Earnings Date	May 8, 2026

About Sprint Bioscience AB

Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2009
• Employees: 30
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 5JA1

Financial Performance

Financial numbers in SEK